According to the results of univariate analyses, plasmatic levels of Hsp90α at diagnosis is a favorable predictor for PFS and OS in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. Here, HSP90AA1 is linked to lung carcinoma.